趋势变化与更重的患者:重新评估妇科肿瘤医生实施的良性指征子宫切除术
该回顾性队列研究利用2014至2021年美国外科质量改进计划数据,分析198,767例子宫切除术中18%(37,707例)由妇科肿瘤医生(GO)实施良性指征手术。GO患者合并症更多、风险更高,总体主要并发症率GO 3.1% vs 良性妇科医生(BG)2.2%(p < 0.001);倾向评分1:1匹配后两组主要并发症率相似(3.0% vs 3.0%,p = 0.55),GO组再手术率(1.2% vs 1.5%,p < 0.01)和伤口并发症率(0.4% vs 0.5%,p = 0.02)更低。八年间GO实施比例显著增加(β = 0.41,R2 = 0.71,p < 0.01),BG相应减少。
要点
- 匹配前GO患者主要并发症率3.1%高于BG的2.2%(p < 0.001),因GO患者风险因素更多。
- 倾向评分匹配后GO与BG主要并发症率相似(3.0% vs 3.0%,p = 0.55)。
- 匹配后GO组再手术率1.2%低于BG组1.5%(p < 0.01),伤口并发症率0.4%低于0.5%(p = 0.02)。
核心结论
- 妇科肿瘤医生正为更高风险患者实施更多良性指征子宫切除术,但匹配队列中GO与BG主要并发症风险相似。
研究设计与样本
- 回顾性队列研究,使用2014至2021年美国外科质量改进计划数据,纳入198,767例良性指征子宫切除术患者。
- 排除妇科或播散性癌症、腹水、非妇科医生手术及剖宫产子宫切除术。
- 主要结局为30天主要(≥3级)并发症,并进行1:1倾向评分匹配比较GO与BG患者。
主要发现
- 198,767例中18%(n = 37,707)良性指征子宫切除术由GO实施。
- GO患者合并症及围手术期特征与BG患者显著不同,风险因素更多。
- 总体GO患者主要并发症率3.1% vs BG 2.2%(p < 0.001),其他复合并发症亦更高。
- 匹配后GO与BG主要并发症率相似(3.0% vs 3.0%,p = 0.55),其他复合并发症无差异。
- 匹配后GO组再手术率1.2% vs BG 1.5%(p < 0.01),伤口并发症率0.4% vs 0.5%(p = 0.02),GO更低。
关键数值与推荐
- 八年间GO实施子宫切除术比例显著增加(β = 0.41,R2 = 0.71,p < 0.01),BG以相同幅度减少。
- BG衰弱患者比例显著下降(β = -0.47,R2 = 0.90,p < 0.01),GO无显著变化(β = -0.36,R2 = 0.38,p = 0.10)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess trends and differences in patient characteristics, complications, and distributions of hysterectomy for benign indications by benign gynecologists (BG) and gynecologic oncologists (GO). METHODS: This retrospective cohort study identified patients undergoing hysterectomy for benign indications using the National Surgical Quality Improvement Program data from 2014 to 2021. Exclusions were made for gynecologic or disseminated cancers, ascites, non-gynecologic surgeons, and cesarean hysterectomies. Primary outcome was major (≥Grade 3) 30-day complications, categorized into any complications, wound, cardiovascular and pulmonary, renal, infectious, andthromboembolic complications. Thirty-day readmissions, reoperations, and mortality were also analyzed. Propensity score matching was performed in a 1:1 match of GO to BG patients and was compared. Linear regressions assessed trends. RESULTS: Among 198,767 patients, 18% (n = 37,707) underwent hysterectomy for benign indications with GO. GO patients exhibited more risk factors for complications and differed significantly from BG patients in comorbidities and perioperative characteristics. Overall, GO patients had higher major complication rates (3.1% vs 2.2%, p < 0.001) and for several other composite complications. After matching, compared to BG, GO-performed hysterectomies had similar rates of major complications (3.0% vs 3.0%, p = 0.55) and no differences in other composite complications, except fewer reoperations (1.2 % vs 1.5%, p < 0.01) and wound complications (0.4% vs 0.5%, p = 0.02) in GO patients. Over the eight years, the percentage of GO-performed hysterectomy (β = 0.41, R2 = 0.71,p < 0.01) increased significantly whereas BG-performed surgeries decreased by the same magnitude. BG had a significant decrease in frail patients (β = -0.47, R2 = 0.90, p < 0.01), but GO did not (β = -0.36, R2 = 0.38, p = 0.10). CONCLUSIONS: GO are performing more hysterectomies for benign indications on higher-risk patients. However, on a matched cohort, risks of major complications were similar between GO and BG.
引用
- Wang CC, Foley OW, Blank SV, et al. Shifting trends and sicker patients: Reassessing hysterectomy performed for benign indications by gynecologic oncologists. Gynecol Oncol. 2024. PMID: 38277920. doi:10.1016/j.ygyno.2024.01.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。